Moderna’s COVID-19 vaccine candidate met primary endpoint in first interim analysis of phase 3 COVE study
On Nov. 15, 2020, an independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of…
COVID-19 patients treated with fluvoxamine had lower likelihood of clinical deterioration over 15 days
On Nov. 14, 2020, JAMA reported that in a preliminary study, adult outpatients with symptomatic COVID-19 treated with…
Cardiac arrest treatment that uses life support machine boosted survival
On Nov. 13, 2020, the NIIH announced that using a life support machine to replicate the functions of…
Albert Einstein College of Medicine received $5 million NIH grant to study HIV and HPV cancers in Africa
On Nov. 13, 2020, Albert Einstein College of Medicine announced that it had received a five-year, $4.9 million…
Vaxart announced additional data from Hamster Challenge Study of its oral COVID-19 vaccine
On Nov. 12, 2020 Vaxart announced additional results from its Hamster Challenge Study. The study evaluated Vaxartﾒs recombinant…
CIRM Board approved four new clinical trials
On Nov.12, 2020, the governing Board of the California Institute for Regenerative Medicine (CIRM) approved four new clinical…
Early mutation in SARS-CoV-2 virus in Europe led to its domination world wide
On Nov. 12, 2020, a study published in Science by a team of researchers in the U.S. and…
Treatments for people with early COVID-19 infection urgent research focus
On Nov. 11, 2020, National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony S. Fauci, M.D., and…
COVID-19 immunity may last six months or more
On Nov. 11, 2020, Howard Hughes Medical Institute Investigator Michel Nussenzweig and his team reported that people who…
Largest set of mammalian genomes revealed species at risk of extinction
On Nov. 11, 2020, An international team of researchers with an effort called the Zoonomia Project announced that…
Pfizer and BioNTech to supply the EU with 200 million doses of mRNA-based vaccine against SARS-CoV-2
On Nov. 11, 2020, Pfizer and BioNTech announced that they had reached an agreement with the European Commission…
Cardinal Health partnered with CDC to support vaccine access for pharmacies
On Nov. 11, 2020, Cardinal Health announced it had reached an agreement with the Centers for Disease Control…
Data showed SARS-CoV-2 reactive T Cells are associated with protection from COVID-19 was published
On Nov. 10, 2020, Oxford Immunotec announced the release of data from a prospective cohort study in keyworkers…
CureVac published detailed interim phase 1 data of its COVID-19 vaccine candidate, CVnCoV
On Nov. 10, 2020, CureVac announced publication of detailed interim Phase 1 data, following the reporting of positive…
ImmunityBio, NantKwest announced positive interim phase 1 safety data of hAd5 COVID-19 vaccine dose study
On Nov. 10, 2020, ImmunityBio and NantKwest, a clinical-stage, natural killer cell-based therapeutics company, announced they had administered…
Altimmune added Lonza as manufacturing partner for supply of AdCOVIDﾙ vaccine candidate for COVID-19
On Nov. 10, 2020, Altimmune announced an agreement with Lonza for the manufacturing of AdCOVIDﾙ, Altimmuneﾒs next-generation, single-dose…
TB Quat Disinfectant Ready-to-Use Cleaner from 3M approved by EPA for use against SARS-CoV-2
On Nov. 10, 2020, 3M announced that its TB Quat Disinfectant Ready-to-Use Cleaner had been approved by the…
BD announced Canadian Government order of 76 million portable, rapid point-of-care antigen tests to detect SARS-CoV-2
On Nov. 10, 2020, BD (Becton, Dickinson) announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the…
Lilly’s neutralizing antibody bamlanivimab received FDA emergency use authorization for treatment of recently diagnosed COVID-19
On Nov. 9, 2020, the FDA granted Emergency Use Authorization (EUA) for Eli Lilly’s investigational neutralizing antibody bamlanivimab…
EUROIMMUN launched quantitative ELISA to measure SARS-CoV-2 antibodies against viral S1 protein
On Nov. 9, 2020, PerkinElmer announced that EUROIMMUN, a PerkinElmer company, had launched the Anti-SARS-CoV-2 QuantiVacTM ELISA (IgG)…
Corvus completed enrollment in phase 1 study of CPI-006 for patients with COVID-19
On Nov. 9, 2020, Corvus Pharmaceuticals announced that it had completed patient enrollment in its Phase 1 study…
ImmunityBioﾒs hAd5 COVID-19 vaccine candidate stimulated memory T-Cell recall in patients with SARS-CoV-2
On Nov. 8, 2020, ImmunityBio announced positive study results for their human Ad5 (hAd5) COVID-19 vaccine candidate, which…
FDA authorized first test that detected neutralizing antibodies from recent or prior SARS-CoV-2 infection
On Nov. 6, 2020, the FDA authorized the first serology test that detected neutralizing antibodies from recent or…
Novartis’ randomized, double-blind, placebo-controlled CAN-COVID trial failed to meet endpoints
On Nov. 5, 2020, Novartis announced data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial…
Relief Therapeutics and NeuroRx announced continuation of RLF-100ﾙ trial for treatment of COVID-19 respiratory failure
On Nov. 5, 2020, RELIEF THERAPEUTICS and NeuroRx announced that the independent Data Monitoring Committee (DMC) voted unanimously…
RECOVERY trial DMC recommended continuing evaluation of REGN-COV2 in hospitalized patients
On Nov. 5, 2020, Regeneron announced an update from the independent data monitoring committee (DMC) for the UK-based…
Neoleukin Therapeutics announced publication of de novo protein decoys that block COVID-19 infection
On Nov. 5, 2020, Neoleukin Therapeutics announced the publication in Science of research describing novel molecules designed to…
Rapid COVID-19 test, Oxsed RaViD Direct, used at Heathrow and trials at Hong Kong International Airport
On Nov. 4, 2020, the University of Oxford announced that its rapid COVID-19 test was being used at…
Research confirmed obesity is a cause of kidney disease
On Nov. 4, 2020, scientists at the University of Oxford announced they had discovered that obesity can increase…
Humanigen announced positive interim phase 3 data of lenzilumabﾙ in patients hospitalized with COVID-19
On Nov. 4, 2020, Humanigen announced positive interim Phase 3 data of lenzilumab in patients hospitalized with COVID-19….